ASX:NEUPharmaceuticals
Why Neuren Pharmaceuticals (ASX:NEU) Is Down 14.6% After Revised DAYBUE Sales and Royalty Outlook
Earlier this week, Neuren Pharmaceuticals announced record Q3 2025 DAYBUE™ sales of US$101.1 million and provided an updated royalty outlook as Acadia Pharmaceuticals narrowed its full-year U.S. net sales forecast for the Rett syndrome drug.
This development highlights both strong demand for DAYBUE and the sensitivity of Neuren's earnings to royalty projections and its partnership with Acadia.
We'll now examine how strong DAYBUE sales growth and the revised royalty outlook influence Neuren's...